ArborGen Inc., the world's leading developer of biotechnology tree seedling products and one of the largest providers of conventional and technology-enhanced seedlings to the global commercial forestry industry, announced today that it has filed a registration statement with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined.
Goldman, Sachs & Co. and Citi will act as joint book-runners for the proposed offering.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Any offer or sale will be made only by means of a written prospectus forming part of the effective registration statement. When available, a preliminary prospectus relating to the proposed offering may be obtained from either: Goldman, Sachs & Co., Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316, or email: [email protected]; or Citigroup Global Markets Inc., Brooklyn Army Terminal, 140 58th Street, 8th Floor Brooklyn, NY 11220, telephone: 800-831-9146, or email: [email protected].